|
CGEM | Cullinan Therapeutics, Inc. |
|
|
CGEM | Cullinan Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.91 |
| Leverage | 6.77% |
| Market Cap | $ 496.3m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -216.2m |
| Margin | 58770.72% |
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.